These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26044936)

  • 1. Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction.
    Hamill V; Ford I; Fox K; Böhm M; Borer JS; Ferrari R; Komajda M; Steg PG; Tavazzi L; Tendera M; Swedberg K
    Am J Med; 2015 Oct; 128(10):1102-1108.e6. PubMed ID: 26044936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):817-21. PubMed ID: 18757091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction.
    Lopes RD; Pieper KS; Stevens SR; Solomon SD; McMurray JJ; Pfeffer MA; Leimberger JD; Velazquez EJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27353607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congestive heart failure with preserved left ventricular systolic function after acute myocardial infarction: clinical and prognostic implications.
    Møller JE; Brendorp B; Ottesen M; Køber L; Egstrup K; Poulsen SH; Torp-Pedersen C;
    Eur J Heart Fail; 2003 Dec; 5(6):811-9. PubMed ID: 14675860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal glucose metabolism in acute myocardial infarction: influence on left ventricular function and prognosis.
    Høfsten DE; Løgstrup BB; Møller JE; Pellikka PA; Egstrup K
    JACC Cardiovasc Imaging; 2009 May; 2(5):592-9. PubMed ID: 19442946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction.
    Ersbøll M; Valeur N; Mogensen UM; Andersen MJ; Møller JE; Velazquez EJ; Hassager C; Søgaard P; Køber L
    J Am Coll Cardiol; 2013 Jun; 61(23):2365-73. PubMed ID: 23563128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J;
    J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.
    Køber L; Torp-Pedersen C; Jørgensen S; Eliasen P; Camm AJ
    Am J Cardiol; 1998 Jun; 81(11):1292-7. PubMed ID: 9631965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy.
    Regnault V; Lagrange J; Pizard A; Safar ME; Fay R; Pitt B; Challande P; Rossignol P; Zannad F; Lacolley P
    Hypertension; 2014 Jan; 63(1):105-11. PubMed ID: 24126172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction: An Analysis From the High-Risk Myocardial Infarction Database Initiative.
    Ferreira JP; Girerd N; Duarte K; Coiro S; McMurray JJ; Dargie HJ; Pitt B; Dickstein K; Testani JM; Zannad F; Rossignol P;
    Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28159825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term significance of Killip class and left ventricular systolic dysfunction.
    Parakh K; Thombs BD; Bhat U; Fauerbach JA; Bush DE; Ziegelstein RC
    Am J Med; 2008 Nov; 121(11):1015-8. PubMed ID: 18954850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
    Shin SH; Hung CL; Uno H; Hassanein AH; Verma A; Bourgoun M; Køber L; Ghali JK; Velazquez EJ; Califf RM; Pfeffer MA; Solomon SD;
    Circulation; 2010 Mar; 121(9):1096-103. PubMed ID: 20176989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
    Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
    Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.